NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) — Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors in securities of Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NASDAQ: SPPI).

If you have purchased Spectrum securities and would like to discuss our investigation, please contact us via email [email protected] or by calling (212) 687-1980.

on 09/22/2022, Reuters reported that advisers to the US Food and Drug Administration “voted against Spectrum Pharmaceuticals’ recommendation.” (SPPI.O) experimental drug used to treat patients with a form of non-small cell lung cancer. The FDA panel voted 9-4 against the oral drug poziotinib, citing low efficacy, high levels of toxicity and lack of dose optimization. The decision of the panel was in accordance with information documents released by the medicines regulator on Tuesday, raising concerns about the treatment’s effectiveness compared to existing medicines such as Daiichi Sankyo‘s and AstraZeneca’s Enhertu. Continue reading”

Following the news, Spectrum’s stock price fell over 33% per share.

This press release may be considered an attorney’s advertisement in some jurisdictions under applicable laws and ethics rules.

WHY CONTACT KAPLAN FOX – Kaplan Fox is a leading national law firm focused on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of securities disputes experience, Kaplan Fox provides the professional experience and track record that clients demand. By prosecuting cases at the federal and state levels, Kaplan Fox has successfully shaped the law by winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, please visit our website at www.kaplanfox.com.

If you have any questions about this investigation, your rights or your interests, please contact:

Jeffrey P Campisi
KAPLAN FOX & KILSHEIMER…